Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials

Fig. 6

Pooled estimates of the network meta-analysis. (A) Pooled hazard ratios (95% credible intervals) for patients with the baseline CNS metastases. (B) Pooled hazard ratios (95% credible intervals) for patients without baseline CNS metastases. Data in each cell are hazard (95% credible intervals) for the comparison of row-defining treatment versus column-defining treatment. Hazard ratios less than 1 favour row-defining treatment. Significant results are in bold. Ale 300 mg, alectinib 300 mg; Ale 600 mg, alectinib 600 mg; Bri, brigatinib; Cer, ceritinib; Chemo, chemotherapy; Cri, crizotinib; Ens, ensartini; Lor, lorlatinib; CNS, central nervous system

Back to article page